Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without Radiotherapy in Second Line Therapy of Metastatic Head and Neck Squamous Cell Carcinoma
NCT03386357Phase 2Terminated
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jul 2018
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Jul 2018; status: terminated.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03386357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386357.